drugset / Trial / NCT00232063

Long-term Study of Ciclosporin for Atopic Dermatitis

NCT00232063

Phase 3 Completed Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In patients with severe adult atopic dermatitis, the safety and efficacy of OL27-400MEPC will be assessed by repeating oral administration at a dose of 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8-12 weeks and recovery until 52 weeks after starting treatment

Timeline

Start
2004-05
Primary completion
2005-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 3 mg/kg Oral

Indications